ArticleEndocrine, metabolic & immune disorders drug targets2026
Evaluation of the Space GlucoseControl System for Managing Stress-Induced Hyperglycemia in ICU Patients: Efficacy and Safety Assessment
Article in Endocrine, metabolic & immune disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite the increasing adoption of the Space GlucoseControl system (SGCs), a novel blood glucose management technique, in critically ill patients, its efficacy and safety warrant further investigation.
objectiveThis study aimed to assess the efficacy and safety of SGCs in managing patients with stress-induced hyperglycemia in the intensive care unit.
methodsA prospective study was conducted involving 22 patients with stress-induced hyperglycemia monitored using the SGCs for 72 hours. Measurements included mean blood glucose, maximum blood glucose, minimum blood glucose, and frequencies of hyperglycemia (> 8.3 mmol/L), hypoglycemia (< 4.4 mmol/L), and target blood glucose (4.4 - 8.3 mmol/L).
resultsMean blood glucose level was significantly different at 24 hours and 48 hours and 24 hours and 72 hours with SGCs (24h vs 48h, P=0.0289; 24h vs 72h, P=0.0252). The times of hyperglycemia (> 8.3 mmol/L) (24h vs 48h, P=0.0289; 24h vs 72h, P=0.0216) was significantly reduced at 48 hours and 72 hours compared to 24 hours. The average interval between blood glucose measurements was significantly extended at 48 hours and 72 hours compared to 24 hours (24h vs 48h, P=0.0037; 24h vs 72h, P=0.0332). The frequency of target blood glucose (4.4 - 8.3 mmol/L) under SGCs blood glucose management at 48 hours and 72 hours was significantly higher than at 24 hours (24h vs 48h, P=0.0395; 24h vs 72h, P=0.0379). There was no significant difference in the times of hypoglycemia (< 4.4 mmol/L) and the highest blood glucose values between 24 hours, 48 hours, and 72 hours with SGCs glucose management (P>0.05). These findings indicate that SGCs blood glucose management can promote greater stability in the blood glucose levels of patients and alleviate the workload of medical staff to some extent.
conclusionSGCs is effective in stabilizing blood glucose levels, increasing the frequency of target blood glucose values, and thereby reducing significant glucose fluctuations, which can improve patient recovery outcomes. Additionally, prolonged use of the SGCs not only optimizes glucose management but also significantly alleviates the workload of nursing staff, enhancing efficiency and allowing for more focused patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.